Olatoyosi Odenike to Clinical Trials as Topic
This is a "connection" page, showing publications Olatoyosi Odenike has written about Clinical Trials as Topic.
Connection Strength
0.494
-
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Mar 27; 145(13):1369-1381.
Score: 0.156
-
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 May; 11(5):e383-e389.
Score: 0.145
-
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.115
-
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109.
Score: 0.062
-
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8.
Score: 0.016